Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 8;25(19):10802.
doi: 10.3390/ijms251910802.

In Silico Design of miniACE2 Decoys with In Vitro Enhanced Neutralization Activity against SARS-CoV-2, Encompassing Omicron Subvariants

Jenny Andrea Arévalo-Romero  1   2 , Gina López-Cantillo  1 , Sara Moreno-Jiménez  1 , Íñigo Marcos-Alcalde  3 , David Ros-Pardo  3 , Bernardo Armando Camacho  1 , Paulino Gómez-Puertas  3 , Cesar A Ramírez-Segura  1
Affiliations

In Silico Design of miniACE2 Decoys with In Vitro Enhanced Neutralization Activity against SARS-CoV-2, Encompassing Omicron Subvariants

Jenny Andrea Arévalo-Romero et al. Int J Mol Sci. .

Abstract

The COVID-19 pandemic has overwhelmed healthcare systems and triggered global economic downturns. While vaccines have reduced the lethality rate of SARS-CoV-2 to 0.9% as of October 2024, the continuous evolution of variants remains a significant public health challenge. Next-generation medical therapies offer hope in addressing this threat, especially for immunocompromised individuals who experience prolonged infections and severe illnesses, contributing to viral evolution. These cases increase the risk of new variants emerging. This study explores miniACE2 decoys as a novel strategy to counteract SARS-CoV-2 variants. Using in silico design and molecular dynamics, blocking proteins (BPs) were developed with stronger binding affinity for the receptor-binding domain of multiple variants than naturally soluble human ACE2. The BPs were expressed in E. coli and tested in vitro, showing promising neutralizing effects. Notably, miniACE2 BP9 exhibited an average IC50 of 4.9 µg/mL across several variants, including the Wuhan strain, Mu, Omicron BA.1, and BA.2 This low IC50 demonstrates the potent neutralizing ability of BP9, indicating its efficacy at low concentrations.Based on these findings, BP9 has emerged as a promising therapeutic candidate for combating SARS-CoV-2 and its evolving variants, thereby positioning it as a potential emergency biopharmaceutical.

Keywords: ACE2-decoys; SARS-CoV-2 variants evading monoclonal antibodies; basic science for translational medicine; in silico design of next-generation therapies for infectious diseases; miniACE2; next-generation treatments for SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The funders had no role in the design of the study, interpretation of data, writing of the manuscript, or the decision to publish the results.

Figures

Figure 1
Figure 1
After 200 ns of MD simulation, the ΔG (A) and Kd (B) values were calculated using the PRODIGY web server [30] for the interaction of each BP with a broad range of RBDs from SARS-CoV-2 viral variants: (Wuhan, PDB: 6m0j [26]; Alpha B.1.1.7, PDB: 8DLK [31]; Beta, PDB: 7VX4 [32]; Delta, PDB: 7W9I [33]; Epsilon, PDB: 8DLV [31]; Gamma, PDB: 8DLQ [31]; Kappa, PDB: 7V86 [34]; Omicron BA.2, PDB: 7ZF7 [35]; Omicron BA.3, PDB: 7XB1 [36]; Omicron BA.1, PDB: 7U0N [37]; Omicron BA.1.1, PDB: 7XAZ [36]; Omicron XBB.1, PDB: 8IOV [38]; Omicron BA.2.75, PDB: 8ASY [39]; Omicron BQ.1.1, PDB: 8IF2 [40]; Omicron BA.4/5, PDB: 8AQS [41]).
Figure 2
Figure 2
In silico designs of BPs expressed in E. coli broadly neutralize SARS-CoV-2 variants through ELISA assays. (A) Neutralization efficacy of BP9 and BP11 ACE2 decoys against Wuhan (wild type), Mu, BA.1, and BA.2 variants compared to ACE2 protein, showing enhanced efficacy and potential for novel BP designs (n = 3 technical replicates shown). (B) IC50 comparative panel between novel BPs and ACE2, suggesting their potential therapeutic use at low doses. (C) Statistical analyses (Tukey’s multiple comparison test performed using GraphPad Prism V10) were performed to calculate the statistical significance of the BPs (BP9 and BP11) compared with the parental hACE2. **** Represent the level of significance.
Figure 3
Figure 3
Stability of BP9 and BP11 at 37 °C and the Serum Matrix. Stability was evaluated by measuring neutralization activity using the cPass SARS-CoV-2 Neutralization Antibody Detection Kit for the BA.1 virus variant, with the ACE2 IC50 value (92.92 µg/mL) as a standard protein concentration under the effects of temperature and serum matrix. (A): Proteins were incubated at room temperature and at 37 °C for 2 h to assess their stability. (C) Proteins were incubated at 37 °C for 2 h in the presence or absence of human serum samples, which were confirmed to lack neutralizing antibodies against SARS-CoV-2 (Supplementary Table S2). Each experiment was performed in three technical replicates. (B,D): The stability coefficient was calculated to identify significant differences in the stability of BP9 and BP11 compared to that of hACE2. The dotted line represents the neutralization cutoff as specified by the kit’s manufacturer. Data are presented as the mean ± standard deviation (SD). p-values were determined using one-way ANOVA (B,D).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924. - DOI - PMC - PubMed
    1. Chen H., Guo J., Wang C., Luo F., Yu X., Zhang W., Li J., Zhao D., Xu D., Gong Q., et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. Lancet. 2020;395:809–815. doi: 10.1016/S0140-6736(20)30360-3. - DOI - PMC - PubMed
    1. Guo Y.-R., Cao Q.-D., Hong Z.-S., Tan Y.-Y., Chen S.-D., Jin H.-J., Tan K.-S., Wang D.-Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak—An update on the status. Mil. Med. Res. 2020;7:11. doi: 10.1186/s40779-020-00240-0. - DOI - PMC - PubMed
    1. COVID-19 Cases|WHO COVID-19 Dashboard. [(accessed on 1 October 2024)]. Available online: https://data.who.int/dashboards/covid19/cases.

MeSH terms

Substances

Supplementary concepts